利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.036 秒)

    COMBINATION VACCINE
    4.
    发明申请
    COMBINATION VACCINE 审中-公开

    公开(公告)号：US20200155668A1

    公开(公告)日：2020-05-21

    申请号：US16781781

    申请日：2020-02-04

    申请人： CureVac AG

    发明人： Karl-Josef KALLEN ,  Thomas KRAMPS ,  Margit SCHNEE ,  Daniel VOSS

    IPC分类号： A61K39/155 ,  A61K39/145 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00

    摘要： The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

    COMBINATION OF VACCINATION AND OX40 AGONISTS
    5.
    发明申请
    COMBINATION OF VACCINATION AND OX40 AGONISTS 审中-公开

    公开(公告)号：US20200030422A1

    公开(公告)日：2020-01-30

    申请号：US16384904

    申请日：2019-04-15

    申请人： CureVac AG

    发明人： Mariola FOTIN-MLECZEK ,  Karl-Josef KALLEN ,  Jan C. SCHMOLLINGER

    IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30

    摘要： The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.

    COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY
    7.
    发明申请
    COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY 审中-公开
    PD-1途径的接种和抑制的组合

    公开(公告)号：US20160206719A1

    公开(公告)日：2016-07-21

    申请号：US15091060

    申请日：2016-04-05

    申请人： CureVac AG

    发明人： Mariola FOTIN-MLECZEK ,  Karl-Josef KALLEN ,  Jochen PROBST

    IPC分类号： A61K39/00 ,  A61K39/395

    CPC分类号： A61K39/0011 ,  A61K39/0005 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/55516 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/76 ,  Y02A50/491 ,  A61K2300/00

    摘要： The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.

    摘要翻译： 本发明涉及疫苗/抑制剂组合物，其包含RNA疫苗，其包含至少一种RNA，其包含至少一种编码至少一种抗原的开放阅读框（ORF）和包含至少一种PD-1途径抑制剂的组合物，优选导向 针对PD-1受体或其配体PD-L1和PD-L2。 本发明还涉及包含这种疫苗/抑制剂组合的组分的药物组合物和试剂盒。 另外，本发明涉及这种疫苗/抑制剂组合的医学用途，药物组合物和包含这种疫苗/抑制剂组合的部分试剂盒，特别是用于预防或治疗肿瘤或癌症疾病或感染性疾病。 此外，本发明涉及RNA疫苗在与PD-1途径抑制剂联合治疗中的用途以及PD-1途径抑制剂在与RNA疫苗联合治疗中的应用。

    COMBINATION VACCINE
    8.
    发明申请
    COMBINATION VACCINE 有权

    公开(公告)号：US20220152193A1

    公开(公告)日：2022-05-19

    申请号：US17590173

    申请日：2022-02-01

    申请人： CureVac AG

    发明人： Karl-Josef KALLEN ,  Thomas KRAMPS ,  Margit SCHNEE ,  Daniel VOSS

    IPC分类号： A61K39/155 ,  A61K39/145 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00

    摘要： The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

    COMBINATION OF VACCINATION AND OX40 AGONISTS
    9.
    发明申请
    COMBINATION OF VACCINATION AND OX40 AGONISTS 有权

    公开(公告)号：US20210369827A1

    公开(公告)日：2021-12-02

    申请号：US17396760

    申请日：2021-08-08

    申请人： CureVac AG

    发明人： Mariola FOTIN-MLECZEK ,  Karl-Josef KALLEN ,  Jan C. SCHMOLLINGER

    IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30

    摘要： The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.

    COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY
    10.
    发明申请
    COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY 审中-公开

    公开(公告)号：US20190381155A1

    公开(公告)日：2019-12-19

    申请号：US16555586

    申请日：2019-08-29

    申请人： CureVac AG

    发明人： Mariola FOTIN-MLECZEK ,  Karl-Josef KALLEN ,  Jochen PROBST

    IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  C07K16/28

    摘要： The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.